ARTICLE | Clinical News

Rindopepimut: Phase II data

October 18, 2010 7:00 AM UTC

A U.S. Phase II trial in 35 patients with newly-diagnosed GBM showed that rindopepimut plus standard of care (SOC) significantly improved median PFS vs. SOC alone (14.2 vs. 6.3 months, p=0.013). Rindopepimut plus SOC also significantly improved median OS vs. SOC alone (26 vs. 15 months, p=0.002). SOC consisted of surgery, radiation and Temodar temozolomide from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Data were published in the Journal of Clinical Oncology. ...